On January 21, the US Food and Drug Administration (FDA) approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome.

For more information, read the FDA Announcement or the Medexus press release.

Posted on 2/7/2025